BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34152410)

  • 21. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis.
    Gupta L; Naveen R; Gaur P; Agarwal V; Aggarwal R
    Semin Arthritis Rheum; 2021 Feb; 51(1):113-120. PubMed ID: 33360322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody.
    Yan TT; Zhang X; Yang HH; Sun WJ; Liu L; Du Y; Xue J
    Clin Rheumatol; 2021 Sep; 40(9):3695-3702. PubMed ID: 33712891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
    Leung AKC; Lam JM; Alobaida S; Leong KF; Wong AHC
    Curr Pediatr Rev; 2021; 17(4):273-287. PubMed ID: 33902423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myositis-associated antibodies predict the severity of lung involvement in adult patients with inflammatory myositis - a cohort study of 70 adult patients with myositis in a single center.
    Marklund J; Hanna B; Jin T; Pullerits R
    Front Med (Lausanne); 2024; 11():1340310. PubMed ID: 38606156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.
    Wang X; Ding Y; Zhou Z; Hou J; Xu Y; Li J
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):6. PubMed ID: 33407621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
    Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
    Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay.
    Wang L; Huang L; Yang Y; Chen H; Liu Y; Liu K; Liu M; Xiao Y; Luo H; Zuo X; Li Y; Xiao X; Zhang H
    Clin Rheumatol; 2018 Oct; 37(10):2731-2739. PubMed ID: 30039266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series.
    Bermudez J; Heim X; Bertin D; Coulon B; Puech B; Bardin N; Reynaud-Gaubert M
    Expert Rev Respir Med; 2020 Aug; 14(8):845-850. PubMed ID: 32394768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
    He L
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies.
    Perron MM; Vasquez-Canizares N; Tarshish G; Wahezi DM
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):92. PubMed ID: 34118936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.
    Fredi M; Cavazzana I; Ceribelli A; Cavagna L; Barsotti S; Bartoloni E; Benucci M; De Stefano L; Doria A; Emmi G; Fabris M; Fornaro M; Furini F; Giudizi MG; Govoni M; Ghirardello A; Iaccarino L; Iannone F; Infantino M; Isailovic N; Lazzaroni MG; Manfredi M; Mathieu A; Marasco E; Migliorini P; Montecucco C; Palterer B; Parronchi P; Piga M; Pratesi F; Riccieri V; Selmi C; Tampoia M; Tripoli A; Zanframundo G; Radice A; Gerli R; Franceschini F;
    Clin Rev Allergy Immunol; 2022 Oct; 63(2):240-250. PubMed ID: 35092577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Clinical Associations of Anti-Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies.
    Yang H; Lu X; Peng Q; Jiang W; Shi J; Zhang Y; Chen H; Wang G
    Arthritis Rheumatol; 2018 Aug; 70(8):1288-1297. PubMed ID: 29534337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical and histopathological features of idiopathic inflammatory myopathies with asymmetric muscle involvement.
    Liu M; Hou Y; Dai T; Lv J; Li W; Zhao Y; Fang Q; Yan C
    J Clin Neurosci; 2019 Jul; 65():46-53. PubMed ID: 31060889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
    Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
    Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties.
    Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
    J Dermatol; 2022 Apr; 49(4):441-447. PubMed ID: 34967032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
    Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
    Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.
    Xu Q; Li QX; Bi FF; Duan HQ; Luo YB; Yang H
    Clin Rheumatol; 2021 Feb; 40(2):613-624. PubMed ID: 32671659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.